There are limited evidence of instrumented measures of gait and balance to determine the functional effects of botulinum toxin injections (BoNT-A) in spasticity after stroke.
OBJECTIVE:
To evaluate the functional changes in gait and balance following upper limb and lower limb BoNT-A in persons with stroke.
METHODS:
A pre-post prospective study of 35 stroke patients with upper and/or lower limb spasticity after focal treatment with BoNT-A. Assessments were at baseline (T0), 6-weeks (T1) and 12-weeks (T2), using validated subjective and objective physical activity measures.
RESULTS:
After BoNT-A injections, significant improvements in most measures of impairments, activity and participation domains were found at T1 (p < 0.05, effect sizes (r) = 0.5–0.9). There was a significant increase in low intensity physical activity (at T1) and sedentary time reductions at both follow-up periods. Instrumented gait/balance measures showed a significant increase in cadence and turn velocity, but no changes in sway measures were found using posturography. Improvements in most outcome measures were maintained at 12-weeks.
CONCLUSION:
BONT-A improved scores in most clinical measures but only in some of the objective gait/balance and physical activity measures. Further robust studies should utilize a larger sample size to better determine the benefits of BoNT-A for stroke-related spasticity.
Ada,L., O’Dwyer,N., O’Neill,E. (2006). Relation between spasticity, weakness and contracture of the elbow flexors and upper limb activity after stroke: An observational study. Disabil Rehabil28(13-14), 891–897. doi: 10.1080/09638280500535165
2.
Australian Institute of Health and Welfare (AIHW). (2016). Australia’s health 2016. Australia’s health series no. 15. Cat. no. AUS 199. Retrieved from Canberra.
3.
Bakheit,A. M. (2004). Optimising the methods of evaluation of the effectiveness of botulinum toxin treatment of post-stroke muscle spasticity. J Neurol Neurosurg Psychiatry75(5), 665–666.
4.
Bakheit,A. M., Maynard,V. A., Curnow,J., Hudson,N., Kodapala,S. (2003). The relation between Ashworth scale scores and the excitability of the alpha motor neurones in patients with post-stroke muscle spasticity. J Neurol Neurosurg Psychiatry74(5), 646–648.
5.
Ballinger,C., Ashburn,A., Low,J., Roderick,P. (1999). Unpacking the black box of therapy – a pilot study to describe occupational therapy and physiotherapy interventions for people with stroke. Clin Rehabil13(4), 301–309.
6.
Bhakta,B. B. (2000). Management of spasticity in stroke. Br Med Bull56(2), 476–485.
7.
Bhakta,B. B., Cozens,J. A., Chamberlain,M. A., Bamford,J. M. (2000). Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: A randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry69(2), 217–221.
8.
Bohannon,R. W., Smith,M. B. (1987). Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther67(2), 206–207.
9.
Buitrago,M. M., Koolwijk,I. (2003). Botulinum toxin for spasticity after stroke. N Engl J Med348(3), 258–259; author reply 258-259.
10.
Cheung,J., Rancourt,A., Di Poce,S., Levine,A., Hoang,J., Ismail,F., … Phadke,C. P. (2015). Patient-identified factors that influence spasticity in people with stroke and multiple sclerosis receiving botulinum toxin injection treatments. Physiother Can67(2), 157–166. doi: 10.3138/ptc.2014-07
11.
Chou,C. Y., Chien,C. W., Hsueh,I. P., Sheu,C. F., Wang,C. H., Hsieh,C. L. (2006). Developing a short form of the Berg Balance Scale for people with stroke. Phys Ther86(2), 195–204.
12.
Cofré Lizama,L. E., Khan,F., Lee,P. V., Galea,M. P. (2016). The use of laboratory gait analysis for understanding gait deterioration in people with multiple sclerosis. Mult Scler22(14), 1768–1776.
13.
Cohen,J. (1988). Statistical power analysis for the behavioural sciences. 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates.
14.
Craig,C. L., Marshall,A. L., Sjostrom,M., Bauman,A. E., Booth,M. L., Ainsworth,B. E., … Oja,P. (2003). International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc35(8), 1381–1395. doi: 10.1249/01.MSS.0000078924.61453.FB
15.
DeJong,G., Horn,S. D., Conroy,B., Nichols,D., Healton,E. B. (2005). Opening the black box of post-stroke rehabilitation: Stroke rehabilitation patients, processes, and outcomes. Arch Phys Med Rehabil86(12 Suppl 2), S1–S7. doi: 10.1016/j.apmr.2005.09.003
16.
Demetrios,M., Gorelik,A., Louie,J., Brand,C., Baguley,I. J., Khan,F. (2014). Outcomes of ambulatory rehabilitation programmes following botulinum toxin for spasticity in adults with stroke. J Rehabil Med46(8), 730–737. doi: 10.2340/16501977-1842
17.
Demetrios,M., Khan,F., Turner-Stokes,L., Brand,C., McSweeney,S. (2013). Multidisciplinary rehabilitation following botulinum toxin and other focal intramuscular treatment for post-stroke spasticity. Cochrane Database Syst Rev (6), CD009689. doi: 10.1002/14651858.CD009689.pub2
18.
Dobkin,B. H. (2003). Botulinum toxin for spasticity after stroke. N Engl J Med348(3), 258–259.
19.
Elia,A. E., Filippini,G., Calandrella,D., Albanese,A. (2009). Botulinum neurotoxins for post-stroke spasticity in adults: A systematic review. Mov Disord24(6), 801–812. doi: 10.1002/mds.22452
20.
Esquenazi,A., Albanese,A., Chancellor,M. B., Elovic,E., Segal,K. R., Simpson,D. M., … Ward,A. B. (2013). Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. Toxicon67, 115–128. doi: 10.1016/j.toxicon.2012.11.025
Francis,H. P., Wade,D. T., Turner-Stokes,L., Kingswell,R. S., Dott,C. S., Coxon,E. A. (2004). Does reducing spasticity translate into functional benefit? An exploratory meta-analysis. J Neurol Neurosurg Psychiatry75(11), 1547–1551. doi: 10.1136/jnn2003.025551
23.
Gracies,J. M., Brashear,A., Jech,R., McAllister,P., Banach,M., Valkovic,P., … International Abobotulinumtoxin, A. A. U. L. S. S. G. (2015). Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: A double-blind randomised controlled trial. Lancet Neurol14(10), 992–1001. doi: 10.1016/S1474-4422(15)00216-1
24.
Granger,C. (1998). The emerging science of functional assessment: Our tool for outcomes analysis. Arch Phys Med Rehabil79, 235–240.
25.
Holden,M. K., Gill,K. M., Magliozzi,M. R., Nathan,J., Piehl-Baker,L. (1984). Clinical gait assessment in the neurologically impaired. Reliability and meaningfulness. Phys Ther64(1), 35–40.
26.
Hyndman,D., Ashburn,A., Stack,E. (2002). Fall events among people with stroke living in the community: Circumstances of falls and characteristics of fallers. Arch Phys Med Rehabil83(2), 165–170.
27.
Khan,F., Amatya,B., YtterbergC.,
Johansson,S.,
Kesselring,J. (2013). Contenet comparision of multidimensional, patient-reported outcome measures in multiple sclerosis and the ICF. Neurodegen Dis Manage3(6), 1–16. doi: 1.
28.
Knottnerus,A., Tugwell,P. (2008). STROBE–a checklist to Strengthen the Reporting of Observational Studies in Epidemiology. J Clin Epidemiol61(4), 323. doi: 10.1016/j.jclinepi.2007.11.006
29.
Lundstrom,E., Smits,A., Borg,J., Terent,A. (2010). Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: The first year after the event. Stroke41(2), 319–324. doi: 10.1161/STROKEAHA.109.558619
30.
Lyle,R. C. (1981). A performance test for assessment of upper limb function in physical rehabilitation treatment and research. Int J Rehabil Res4(4), 483–492.
31.
Mancini,M., King,L., Salarian,A., Holmstrom,L., McNames,J., Horak,F. B. (2011). Mobility lab to assess balance and gait with synchronized body-worn sensors. J Bioeng Biomed Sci, Suppl 1, 007. doi: 10.4172/2155-9538.S1-007
32.
Persson,C. U., Hansson,P. O., Lappas,G., Danielsson,A. (2016). Physical activity levels and their associations with postural control in the first year after stroke. Phys Ther96(9), 1389–1396. doi: 10.2522/ptj.20150367
33.
Rowland,L. P. (2002). Stroke, spasticity, and botulinum toxin. N Engl J Med347(6), 382–383. doi: 10.1056/NEJMp020071
34.
Salter,K., Campbell,N., Richardson,M., Mehta,S., Jutai,J., Zettler,L., … Teasell,R. (2013). Outcome measures in stroke rehabilitation. In
CotoiA &
TeasellR (Eds.), Evidence-Based Review of Stroke Rehabilitation. London: EBRSR Research Group.
35.
Saso,A., Moe-Nilssen,R., Gunnes,M., Askim,T. (2016). Responsiveness of the berg balance scale in patients early after stroke. Physiother Theory Pract32(4), 251–261. doi: 10.3109/09593985.2016.1138347
36.
Stevenson,V. L. (2010). Rehabilitation in practice: Spasticity management. Clin Rehabil24(4), 293–304. doi: 10.1177/0269215509353254
37.
Teasell,R., Foley,N., Pereira,S., Sequeira,K., Miller,T. (2012). Evidence to practice: Botulinum toxin in the treatment of spasticity post stroke. Top Stroke Rehabil19(2), 115–121. doi: 10.1310/tsr1902-115
Turner-Stokes,L., Thu,A., Williams,H., Casey,R., Rose,H., Siegert,R. J. (2014). The neurological impairment scale: Reliability and validity as a predictor of functional outcome in neurorehabilitation. Disabil Rehabil36(1), 23–31. doi: 10.3109/09638288.2013.775360
40.
Watkins,C. L., Leathley,M. J., Gregson,J. M., Moore,A. P., Smith,T. L., Sharma,A. K. (2002). Prevalence of spasticity post stroke. Clin Rehabil16(5), 515–522.
41.
World Health Organization (WHO). (2001). International classification of functioning, disability and health (ICF), Geneva: WHO.
